何敏, 于汇民, 黄宪章. ACE2基因, 高血压防治新策略[J]. 循证医学, 2014, 14(5): 313-316. DOI: 10.3969/j.issn.1671-5144.2014.05.020
    引用本文: 何敏, 于汇民, 黄宪章. ACE2基因, 高血压防治新策略[J]. 循证医学, 2014, 14(5): 313-316. DOI: 10.3969/j.issn.1671-5144.2014.05.020
    HE Min, YU Hui-min, HUANG Xian-zhang. Angiotensin-Converting Enzyme 2, A Promising Therapeutic Target for Prevention of Hypertension[J]. Journal of Evidence-Based Medicine, 2014, 14(5): 313-316. DOI: 10.3969/j.issn.1671-5144.2014.05.020
    Citation: HE Min, YU Hui-min, HUANG Xian-zhang. Angiotensin-Converting Enzyme 2, A Promising Therapeutic Target for Prevention of Hypertension[J]. Journal of Evidence-Based Medicine, 2014, 14(5): 313-316. DOI: 10.3969/j.issn.1671-5144.2014.05.020

    ACE2基因, 高血压防治新策略

    Angiotensin-Converting Enzyme 2, A Promising Therapeutic Target for Prevention of Hypertension

    • 摘要: 血管紧张素转换酶2是肾素-血管紧张素-醛固酮系统新成员,主要通过调节血管紧张素Ⅱ水平参与血压调控。血管紧张素转换酶2表达或活性异常不仅参与高血压病的发生、发展过程,还与肾素-血管紧张素-醛固酮系统阻断剂的降压疗效相关,因而成为高血压防治的新靶标。本文将综合阐述血管紧张素转换酶2参与血压调控的机制,并且分析以该支路为靶标的高血压药物治疗策略。

       

      Abstract: Abstract: Angiotensin-converting enzyme 2 (ACE2) is a new component of the renin-angiotensin-aldosterone system (RAAS), which functions as a key enzyme in modulating blood pressure through metabolizing angiotensin Ⅱ(AngⅡ).The abnormal expression or catalytic activity of ACE2 may not only contribute to the development of hypertension, but also correlate with the curative effects of RAAS inhibitors.Based on these observations, ACE2 may be considered as a novel therapeutic tool for the treatment of cardiovascular diseases.This review summarizes the regulatory mechanism of ACE2, and discusses its therapeutic role for the prevention of hypertension.

       

    /

    返回文章
    返回